 This phase III study is assessing the drugs safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss ISSNHL. The active pharmaceutical ingredient of AM-111 is the JNK inhibitor D-JNKI-1, a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase JNK ligand. 